title: "Reaction to cytarabine (Ara-C) treatment in patients with concurrent Staphylococcus aureus infection: a coalition between Ara-C and superantigens?".
authors.forename: S
authors.initials: S
authors.lastname: Savaşan
authors.forename: I
authors.initials: I
authors.lastname: Warrier
authors.forename: E
authors.initials: E
authors.lastname: Can
authors.forename: M
authors.initials: M
authors.lastname: Can
authors.forename: G
authors.initials: G
authors.lastname: Gedikoğlu
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002675:Child, Preschool; D003561:Cytarabine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000209:etiology / Q000276:immunology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D012772:Shock, Septic / Q000209:etiology / Q000276:immunology; D013203:Staphylococcal Infections / Q000150:complications* / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology*; D018089:Superantigens
chemical_list: D000964:Antimetabolites, Antineoplastic; D018089:Superantigens; D003561:Cytarabine